Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for ...

Stifel Nicolaus lowered their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th.

Barclays (LON:BARC) initiated coverage on Exact Sciences (NASDAQ:EXAS), a leading molecular diagnostics company with a market capitalization of $10.14 billion, assigning the stock an Overweight rating ...

Any in your portfolio? Citigroup raises price target on ULTA and SNAP. Centers for Medicare & Medicaid Services finalizes 2025 pricing for Exact Sciences' Cologuard Plus, raising Medicare ...